Featured Research

from universities, journals, and other organizations

New synthetic compound created with HIV-fighting promise

Date:
January 18, 2011
Source:
The Scripps Research Institute
Summary:
Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a research team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

With the report of their work scheduled to appear in the online Early Edition of Proceedings of the National Academy of Sciences this week, the researchers now plan to optimize the compound's pharmaceutical potential so that it can be pursued as a drug candidate.

The plant Hypericum chinense, known in Japan as biyouyanagi, produces beautiful yellow flowers and, as it happens, potent chemical compounds known as biyouyanagins that have already shown promising anti-HIV and anti-tumor activity. That got the attention of K.C. Nicolaou, who holds the titles chair of the Department of Chemistry, Aline W. and L.S. Skaggs Professor of Chemical Biology, and Darlene Shiley Chair in Chemistry at Scripps Research. Nicolaou's interest was also piqued because the plant is from the same family that produces St. John's wort, and the biyouyanagins possess an intriguing molecular architecture.

"It was the perfect recipe for convincing a synthetic chemist to get into the game," said Nicolaou, who spearheaded the project in collaboration with a number of Scripps Research colleagues. "It seemed like there was so much to be discovered."

Best of Both Worlds

Within the biomedical field there are some researchers that argue natural products are the best route to new drug discovery. Others laud the potential of designing completely synthetic drugs. "I belong to both camps," says Nicolaou, because he prefers to start with natural products and then modify them in a variety of ways to create new synthetic products with improved potential. "The power of this method is that it allows us to build on the natural structures to make a whole new and diverse family of compounds."

An unexpected side result of the group's initial work was the discovery that the structure previously reported for the biyouyanagins was slightly off. With the proper structures in hand, the Nicolaou team recognized it could induce formation of critical bonds that join the two domains of the molecules by bombarding the right chemical building blocks with ultraviolet light.

This technique, known as photocycloaddition, allowed the scientists to synthesize the two known biyouyanagins as well as a third type not yet discovered in nature. The scientists then began combining a variety of different building blocks -- some commercially available and others they produced in the lab -- using the photocycloaddition to build a library of about 50 analogs, compounds similar to the originals but with significant chemical variations.

The resulting compounds then went in groups to various collaborating Scripps Research laboratories. Professor Dennis Burton's lab analyzed the compounds' ability to inhibit replication of HIV. Chair of the Department of Chemical Physiology Ben Cravatt's team looked at anti-inflammatory potential. Professor Juan de la Torre's group examined effects against LCMV, the prototype member of the arenavirus family that includes several causative agents of deadly hemorrhagic fever disease in West Africa and South America.

All of the compounds in the team's new library are, like aspirin, considered small molecules. Nicolaou believes these offer the best biomedical potential. Larger molecules such as proteins are finding new medical applications, but have to be injected and are often short-lived and very expensive.

"If you can discover small molecules that work, they're affordable and they last long enough in the body to do their jobs," he said. "Those are the magic bullets."

A Promising Lead

One compound from the new library, number 53, stood out. One side of its structure is essentially the same as that of a natural biyouyanagin, while the other side is a departure comprising a structural motif like the bases found in DNA. In the HIV testing, it compared favorably with the well-known AIDS drug AZT, though it is not yet as potent. In the anti-inflammatory tests, it was as potent or more so than commercially available products. This particular compound hasn't been tested for its potential against arenaviruses, but Nicolaou is hopeful the team will eventually find interesting activity there as well.

"We were certainly excited to see those results," says Nicolaou. "It's quite a promising lead." Next, the team will tinker with 53's initial structure in search of modifications that will increase its potency. Once its biomedical activities are optimized, the group will consider pushing the compound toward the drug-testing process.

This work was funded by the National Institutes of Health, the Skaggs Institute for Chemical Biology, the Universita degli Studi di Urbino "Carlo Bo," the Japanese Society for the Promotion of Science, the Natural Sciences and Engineering Research Council of Canada, and the National Institute on Drug Abuse.

In addition to Nicolaou, Burton, Cravatt, and de la Torre, authors of the paper, titled "Design, synthesis, and biological evaluation of a biyouyanagin compound library," were Silvano Sanchini, David Sarlah, Gang Lu, T. Robert Wu, Daniel Nomura, Beatrice Cubitt, and Ann Hessell, all from The Scripps Research Institute.


Story Source:

The above story is based on materials provided by The Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. C. Nicolaou, Silvano Sanchini, David Sarlah, Gang Lu, T. Robert Wu, Daniel K. Nomura, Benjamin F. Cravatt, Beatrice Cubitt, Juan C. De La Torre, Ann J. Hessell, Dennis R. Burton. Organic Synthesis toward Small-Molecule Probes and Drugs Special Feature: Design, synthesis, and biological evaluation of a biyouyanagin compound library. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1015258108

Cite This Page:

The Scripps Research Institute. "New synthetic compound created with HIV-fighting promise." ScienceDaily. ScienceDaily, 18 January 2011. <www.sciencedaily.com/releases/2011/01/110118142754.htm>.
The Scripps Research Institute. (2011, January 18). New synthetic compound created with HIV-fighting promise. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2011/01/110118142754.htm
The Scripps Research Institute. "New synthetic compound created with HIV-fighting promise." ScienceDaily. www.sciencedaily.com/releases/2011/01/110118142754.htm (accessed April 17, 2014).

Share This



More Matter & Energy News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

German Researchers Crack Samsung's Fingerprint Scanner

German Researchers Crack Samsung's Fingerprint Scanner

Newsy (Apr. 16, 2014) German researchers have used a fake fingerprint made from glue to bypass the fingerprint security system on Samsung's new Galaxy S5 smartphone. Video provided by Newsy
Powered by NewsLook.com
Porsche CEO Says Supercar Is Not Dead: Cue the Spyder 918

Porsche CEO Says Supercar Is Not Dead: Cue the Spyder 918

TheStreet (Apr. 16, 2014) The Porsche Spyder 918 proves that, in an automotive world obsessed with fuel efficiency, the supercar is not dead. Porsche North America CEO Detlev von Platen attributes the brand's consistent sales growth -- 21% in 2013 -- with an investment in new technology and expanded performance dynamics. The hybrid Spyder 918 has 887 horsepower and 944 lb-ft of torque, but it can run 18 miles on just an electric charge. The $845,000 vehicle is not a consumer-targeted vehicle but a brand statement. Video provided by TheStreet
Powered by NewsLook.com
Industry's Optimism Shines At New York Auto Show

Industry's Optimism Shines At New York Auto Show

Newsy (Apr. 16, 2014) After seeing auto sales grow last month, there's plenty for the industry to celebrate as it rolls out its newest designs. Video provided by Newsy
Powered by NewsLook.com
Ford Mustang Fetes Its 50th Atop Empire State Building

Ford Mustang Fetes Its 50th Atop Empire State Building

AFP (Apr. 16, 2014) Ford celebrated the 50th birthday of its beloved Mustang by displaying a new model of the convertible on top of the Empire State Building in New York. Duration: 00:28 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins